Together, these mutations account for approximately 85% of the EGFR mutations observed in lung cancer [46, 48, 66]; tumors with these mutations are highly sensitive to treatment with erlotinib, gefitinib, and the second-generation EGFR inhibitor afatinib [63, 67–69]. Here, EGFR is linked to lung cancer.